India's AIMIL Pharmaceuticals, manufacturer and marketer of ayurvedic proprietary and classical medicines, is all set to take its products to European markets, starting with the Czech Republic.
"AIMIL is starting its Europe growth story with Czech Republic," the company said in a statement on Thursday, adding that some of the products will start becoming available from May this year.
AIMIL Pharmaceuticals EU, as it will be known in Europe, will focus on six to eight therapeutic areas such as kidney stones, acne, aphrodisiacs, orthopaedic, diabetes, respiratory, liver preparation and oral hygiene.
"We are very excited to enter the Europe market since it is our vision to become a significant global player by providing high quality, affordable and innovative solutions in medicine and treatment and desire to serve the people to live healthily and a happy life," said K K Sharma, Managing Director, AIMIL Pharmaceuticals (I) Ltd.
"Europe launch is a definite milestone in that journey," Sharma added.
AIMIL, which has already made a mark with its products in South Asian markets, especially Kuwait, Sri Lanka and Nepal, has technical collaboration in Canada and Commonwealth countries.
Over the years, AIMIL has worked in close collaboration with the Government of India's Defence Research and Development Organisation (DRDO) and Council of Scientific and Industrial Research (CSIR) for research and development.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)